Docosahexaenoic Acid Reduces Levodopa-induced Dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkeys

Overview

Journal Ann Neurol

Specialty Neurology

Date 2006 Jan 27

PMID 16437566

Citations 22

Authors

Pershia Samadi

Laurent Gregoire

Claude Rouillard

Paul J Bedard

Therese Di Paolo

Daniel Levesque

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.

Methods: We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy.

Results: DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease.

Interpretation: These results suggest that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients.

Citing Articles

Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.

Boelens Keun J, Arnoldussen I, Vriend C, van de Rest O Adv Nutr. 2021; 12(6):2265-2287.

PMID: 34113965 PMC: 8634393. DOI: 10.1093/advances/nmab060.

Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration.

Gentile F, Doneddu P, Riva N, Nobile-Orazio E, Quattrini A Int J Mol Sci. 2020; 21(20).

PMID: 33050475 PMC: 7590163. DOI: 10.3390/ijms21207471.

N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders.

Healy-Stoffel M, Levant B CNS Neurol Disord Drug Targets. 2018; 17(3):216-232.

PMID: 29651972 PMC: 6563911. DOI: 10.2174/1871527317666180412153612.

Non-human primate models of PD to test novel therapies.

Morissette M, Di Paolo T J Neural Transm (Vienna). 2017; 125(3):291-324.

PMID: 28391443 DOI: 10.1007/s00702-017-1722-y.

Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.

Dyall S Front Aging Neurosci. 2015; 7:52.

PMID: 25954194 PMC: 4404917. DOI: 10.3389/fnagi.2015.00052.